¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Population reports. Series G, Prostaglandins."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® population ÇÑ±Û ¸ðÁý´Ü
¼³¸í   
  Åë°è¿ë¾î·Î, Åë°èÀûÀΠ°üÂûÀÇ ´ë»óÀÌ µÇ´Â Áý´Ü Àüü. ÃøÁ¤À̳ª Á¶»ç¸¦ Çϱâ À§ÇÏ¿© Ç¥º»À» »Ì¾Æ³»´Â ¹ÙÅÁÀÌ µÈ´Ù. ÀÌ¿¡ ´ëÇØ ¸ðÁý´Ü¿¡¼­ ¼±ÃâµÈ ÀϺδ ǥº»À̶ó°í ÇÑ´Ù. ½ÇÁ¦ Á¶»ç¿¡¼­´Â ¸ðÁý´ÜÀÇ ¸ðµç Á¤º¸¸¦ ÆÄ¾ÇÇϴ °ÍÀÌ °ï¶õÇϱ⠶§¹®¿¡, ÃßÃâÇѠǥº»¿¡ ±âÃÊÇÏ¿© ¸ðÁý´Ü¿¡ ´ëÇØ¼­ °á·ÐÀ» ³»¸®°Ô µÈ´Ù. 
¿µ¹® upper GI series ÇÑ±Û »óºÎÀ§Àå°üÁ¶¿µ¼ú
¼³¸í   
  X-¼± »çÁø¿¡¼­ Àß ³ªÅ¸³ª´Â Á¶¿µÁ¦(¹æ»ç¼±ÃÔ¿µ»ó¿¡¼­ ÇϾé°Ô ³ªÅ¸³ª ÁÖÀ§Á¶Á÷°ú °¨º°ÀÌ ¿ëÀÌÇÏ´Ù)¸¦ ¼·ÃëÇÑ ÈÄ ½Äµµ, À§, »ùâÀÚ, ÀÛÀºÃ¢ÀÚ»óºÎ±îÁö X-¼± ÃÔ¿µÇϹǷνá, ±×°÷ ¼ÒÈ­°ü³»ÀÇ ÀÌ»óº´ÅÍ¿©ºÎ¸¦ °Ë»çÇϴ °Í. Á¶¿µÁ¦´Â ÁַΠ¹Ù·ýÀ» »ç¿ëÇϸ破õ ¼±¸íÇÑ ¿µ»óÀ» ¾ò±âÀ§ÇØ ¹ßÆ÷Á¦¸¦ ÇÔ²² ¼·ÃëÇÏ¿© ¹Ù·ý°ú °ø±âÀÇ ÀÌÁßÁ¶¿µÃÔ¿µÀ» Çϱ⵵ ÇÑ´Ù. ½Äµµ¾Ï, À§¾Ï ¹× ¼ÒÈ­¼º±Ë¾ç°ú ±×¹Û¿¡ ´Ù¾çÇÑ º´º¯ÀÇ Áø´Ü¿¡ È¿°úÀûÀ¸·Î »ç¿ëµÈ´Ù.
¿µ¹® population ÇÑ±Û Àα¸, ¸ðÁý´Ü
¼³¸í   
  ¼ö ¼¼´ë¸¦ ÅëÇÏ¿© À¯Àü¼º ¹× ¹®È­Àû °è¼Ó¼º¿¡ ÀÇÇÏ¿© Æ¯Â¡Áö¿öÁö°í, ÀÎÁ¢ÇÏ¿© ºÐÆ÷Çϰí Àִ ÀÏÁ¤ÇÑ Áö¿ª¿¡ »ç´Â »ç¶÷ÀÇ ¼ö.
¿µ¹® small bowel series ÇÑ±Û ÀÛÀºÃ¢ÀÚ Á¶¿µ¼ú, ¼ÒÀå Á¶¿µ¼ú
¼³¸í   
  ¹æ»ç¼± Á¶¿µÁ¦(¹æ»ç¼±°Ë»ç¿¡¼­ ´Ù¸¥ ºÎÀ§¿Í ´ëÁ¶µÇ´Â ¾ÆÁÖ Èò»öÀ» ¶ì´Â ¹°Áú)ÀΠ¹Ù·ýÀ» ¼·ÃëÇÑ µÚ, ÃÔ¿µÇϴ ÀÛÀºÃ¢ÀÚÀÇ ±âº»ÀûÀΠ¹æ»ç¼± °Ë»ç·Î¼­, ¹æ¹ýÀº 200~300mLÀÇ ¹Ù·ýÀ» ¸ÔÀºµÚ ¹Ù·ýÀÌ ÀÛÀº Ã¢ÀÚ¸¦ Åë°úÇϴ µ¿¾È Á¤±ÔÀû °£°ÝÀ¸·Î ¹æ»ç¼± »çÁøÀ» ÂïÀ½. ÀϹÝÀûÀ¸·Î 2~3½Ã°£ÀÌ °É¸².
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aromatic series
    ¹æÇâÁ·°è¿­
  • aliphatic series
    Áö¹æÁ·°è¿­
  • discrete series
    ºÒ¿¬¼Ó¼ö¿­
  • exponential series
    Áö¼ö±Þ¼ö
  • granulocytic series
    °ú¸³±¸°è¿­
  • homologous series
    µ¿Á·°è¿­
  • ionization series
    ÀÌ¿ÂÈ­°è¿­
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • series
    1. °è¿­ 2. ±Þ¼ö 3. Á÷·Ä
  • series elastic component
    Á÷¿­Åº·Â¼ººÐ
  • series limit
    °è¿­±ØÇÑ
  • dynamic population
    À¯µ¿Àα¸
  • island population
    °í¸³Àα¸Áý´Ü
  • infinite population
    ¹«ÇѸðÁý´Ü
  • model population
    ¸ðÇüÀα¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • series
    °è¿­, ±Þ¼ö
  • population dynamics
    Àα¸µ¿ÅÂ
  • population mean
    ¸ðÆò±Õ
  • population
    Àα¸, ¸ðÁý´Ü
  • reference population
    ±âÁØÁý´Ü
  • standard population
    Ç¥ÁØÀα¸
  • population study
    Àα¸Á¶»ç
  • population variance
    ¸ðÁý´ÜºÐ»ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aliphatic series
    Áö¹æ°è¿­
  • aromatic series
    ¹æÇâÁ·°è¿­
  • commutator series
    ±³È¯ÀÚ¿­
  • series elastic component
    Á÷¿­Åº·Â¼ººÐ
  • discrete series
    ºÒ¿¬¼Ó¼ö¿­
  • exponential series
    Áö¼ö±Þ¼ö
  • granulocytic series
    °ú¸³±¸°è¿­
  • homologous series
    µ¿Á·°è¿­
  • hypergeometric series
    ÃʱâÇϱ޼ö
  • ionization series
    ÀÌ¿ÂÈ­°è¿­
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lyotropic ionic series
    À̾×À̿°迭
  • series limit
    °è¿­, ±ØÇÑ
  • series
    °è¿­, ±Þ¼ö
  • dynamic population
    À¯µ¿Àα¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hofmeister s series =lyotropic s.
    È£ÇÁ¸¶À̽ºÅͰ迭(¡­Í§æê).
  • aliphatic series
    Áö¹æ°è¿­.
  • arithmetic series
    µîÂ÷±Þ¼ö.
  • aromatic series
    ¹æÇâÁ·¿­(¡­ðéæê).
  • gallbladder series
    ´ã³¶Á¶¿µ°Ë»ç.
  • gallbladder series
    ´ã³²Á¶¿µ°Ë»ç
  • homologous series
    µ¿Á·°è¿­(¡­Í§æê).
  • hypergeometric series
    ÃʱâÇϱ޼ö(̧˻̰˻Ëà).
  • principal series
    ÁÖ°è¿­(̡˭Ëç).
  • population
    Àα¸, ¸ðÁý´Ü(ËÎ̤ËÀ) Åë°èÀÇ , Áý´Ü, °³Ã¼±º(˧̧˴).
  • population density
    Àα¸¹Ðµµ(ÊÙËÑ̬).
  • population dynamics
    Áý´Üµ¿ÅÂ, Àα¸µ¿·ÂÇÐ(ÊÙËÄËç̰).
  • population equivalent
    Àα¸´ç·®(ÊÙËÀËâ).
  • population genetics
    Áý´ÜÀ¯ÀüÇÐ(ÊÙËôËøÌ°).
  • population growth
    Àα¸¼ºÀå(ËöË´ËÛËö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gastrointestinal series =GI series
    ¹æ»ç À§Àå°üÁ¶¿µ¼ú.
  • aliphatic series
    Áö¹æ°è¿­.
  • arithmetic series
    µîÂ÷±Þ¼ö.
  • aromatic series
    ¹æÇâÁ·¿­(¡­ðéæê).
  • binomial series
    ÀÌÇ×±Þ¼ö(ËöÌ´Ë»Ëà).
  • cardiac series
    ½ÉÀå¾¾¸®Áî (ãýíô - )
  • cardiac series
    ½ÉÀå½Ã¸®Áî.
  • commutator series
    ±³È¯ÀÚ¿­(Ë´Ì·ËöËç).
  • commutator series
    ±³È¯ÀÚ¿­(Îßüµí­æê).
  • discrete series
    ºÒ¿¬¼Ó¼ö¿­(ËÓËçËÛËàËç).
  • exponential series
    Áö¼ö±Þ¼ö(ÊÙË»Ëà).
  • gallbladder series
    ´ã³¶Á¶¿µ°Ë»ç.
  • gallbladder series
    ´ã³²Á¶¿µ°Ë»ç
  • homologous series
    µ¿Á·°è¿­(¡­Í§æê).
  • hypergeometric series
    ÃʱâÇϱ޼ö(̧˻̰˻Ëà).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • population
    "Àα¸(ìÑÏ¢), Áý´Ü(ó¢Ó¥), ÀÔÀÚ´Ü(Ø£í­Ó¥)"
  • chaotropic series
    ¹«Áú¼­(Ùíòñßí) ¾¾¸®½º
  • decay series
    "ºØ±« °è¿­(ÝÚÎÕ֪ͧ), (µ¿) radioactive series"
  • eluotropic series
    ¿ë¸® ¼­¿­ (éÁ×îßíÖª)
  • globo-series glycosphingolipids
    ±Û·Îº¸°è¿­(֪ͧ) ´ç(ÓØ)½ºÇΰíÁöÁú(ò·òõ)
  • Hofmeister series
    È£ÇÁ¸¶À̽ºÅÍ °è¿­(֪ͧ)
  • homologous series
    µ¿Á· °è¿­(ÔÒðé֪ͧ)
  • lacto-series glycosphingolipid
    ¶ôÅä°è¿­(֪ͧ) ±Û¶óÀÌÄÚ½ºÇΰíÁöÁú(ò·òõ)
  • lyotropic series
    À̾װ迭(ìÆäû֪ͧ)
  • radioactive series
    ¹æ»ç¼º °è¿­(Û¯ÞÒàõ֪ͧ)
  • Trappe's eluotropic series
    Æ®¶óÆä ¿ë¸®¼­¿­(éÁ×îßíÖª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gallbladder series
    ´ã³¶Á¶¿µ°Ë»ç
  • gastrointestinal series
    À§Àå°üÁ¶¿µ¼ú
  • small bowel series
    ¼ÒÀåÁ¶¿µ¼ú
  • upper gastrointestinal series
    »óºÎÀ§Àå°üÁ¶¿µ¼ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PGA1-3 prostaglandins A1 to A3
PGE, PGE1, PGE2 prostaglandins E, E1, E2
PGF, PGF1, PGF2 prostaglandins F, F1, F2
UGIS Upper Gastro-Intestinal Series
FMS fat-mobilizing substance; Fellow of the Medical Society; fibromyalgia syndrome; full mouth series
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SEC Series elastic component
PGE1 Prostaglandins E1
PGF2 alpha Prostaglandins F2 alpha
PGE2 Prostaglandins E1 and E2
CPS Current Population Survey
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 3362
    JournalTitle: Population reports. Series G, Prostaglandins.
    MedAbbr: Popul Rep G
    ISSN: 0091-9276
    ESSN:
    IsoAbbr:
    NlmId: 376216
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aromatic series
    ¹æÇâÁ· ¿­
  • Balmer's series
    ¹ß¸Ó °è¿­
  • case-series evaluation
    »ç·Ê Æò°¡
  • electrochemical series
    Àü±â È­ÇÐ ¼­¿­
  • homologous series
    µ¿Á· °è¿­
  • series Á·, ¾Æ°­ÀÇ ÇÏÀ§ÀÌ°í ¸ñÀÇ »óÀ§ÀÎ ºÐ·ùÇÐÀû ¹üÁÖ.

    seriflux

    ¼ö¾ç ¹è¼³¾×, Àå¾× ¹æÃâ, ¿¯Àº ¼ö¾ç¾× ¹æÃâ
  • small bowel series
    ¼ÒÀå Á¶¿µ¼ú
  • broader population
    ´õ Å« Áý´Ü
  • model population
    ¸ðÇü Àα¸
  • non-injury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • noninjury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • nonpatient population
    ºñȯÀÚ Áý´Ü
  • population
    Àα¸, ¸ðÁý´Ü, Áý´Ü, °³Ã¼±º
  • population problem
    Àα¸ ¹®Á¦
  • younger population
    û³âÃþ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
annual reports Annual statements concerning the administrative and operational functions of an institution or organization.
(12 Dec 1998)
prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes.
(12 Dec 1998)
prostaglandins a (13e,15s)-15-hydroxy-9-oxoprosta-10,13-dien-1-oic acid (pga(1)); (5z,13e,15s)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid (pga(2)); (5z,13e,15s,17z)-15-hydroxy-9-oxoprosta-5,10,13,17-tetraen-1-oic acid (pga(3)). A group of naturally occurring secondary prostaglandins derived from pge. Pga(1) and pga(2) as well as their 19-hydroxy derivatives are found in many organs and tissues.
(12 Dec 1998)
prostaglandins a, synthetic Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga.
(12 Dec 1998)
prostaglandins b Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities.
(12 Dec 1998)
prostaglandins d Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects.
(12 Dec 1998)
prostaglandins e (11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (pge(1)); (5z,11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (pge(2)); and (5z,11 alpha,13e,15s,17z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (pge(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities.
(12 Dec 1998)
prostaglandins e, synthetic Analogs or derivatives of prostaglandins e that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pge.
(12 Dec 1998)
prostaglandins f (9 alpha,11 alpha,13e,15s)-9,11,15-trihydroxyprost-13-en-1-oic acid (pgf(1 alpha)); (5z,9 alpha,11,alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (pgf(2 alpha)); (5z,9 alpha,11 alpha,13e,15s,17z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (pgf(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring pgf have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.
(12 Dec 1998)
prostaglandins f, synthetic Analogs or derivatives of prostaglandins f that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pgf.
(12 Dec 1998)
prostaglandins g A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. most frequently encountered member of this group is the prostaglandin g2.
(12 Dec 1998)
prostaglandins h A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin h2.
(12 Dec 1998)
prostaglandins, synthetic Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity.
(12 Dec 1998)
aromatic series All the compounds derived from benzene, or similar cyclic compounds that obey Huckel's rule, distinguished from those compounds that are acyclic or that contain rings that lack the conjugated double bond structure characteristic of benzene.
(05 Mar 2000)
granulocytic series <haematology> The cells in the several stages of development in the bone marrow leading to the mature granulocyte of the circulation, e.g., myeloblasts, different stages of the myelocyte, granulocytes.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • population
    Àα¸
  • population
    Àα¸;ÁÖ¹Î;¸ðÁý´Ü
  • population biology
    Áý´Ü »ý¹°ÇÐ
  • population crisis
    Àα¸ Áõ°¡¿¡ ÀÇÇÑ À§±â
  • population density
    Àα¸ ¹Ðµµ
  • population explosion
    ±Þ°ÝÇÑ Àα¸ Áõ°¡;Àα¸ Æø¹ß
  • population genetics
    Áý´Ü À¯ÀüÇÐ
  • population inversion
    ¹ÝÀü ºÐÆ÷
  • a series fo
    ÀÏ·ÃÀÇ
  • series
    ¿¬¼ÓµÈ °Í
  • actinide series
    ¾ÇƼ´Ïµå °è¿­;¹æ»ç¼±¿ø¼Ò
  • arithmetic series
    µîÂ÷±Þ¼ö
  • geometric series
    ±âÇÏ(µîºñ)±Þ¼ö
  • harmonic series
    Á¶È­ ±Þ¼ö
  • methane series
    ¸Þź ¿­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á